Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 58, Issue 18, Pages 7419-7430Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.5b00930
Keywords
-
Categories
Funding
- National Institutes of Health [P01-GM091743]
- V Foundation for Cancer Research (V Translational Award)
- University of Minnesota (Innovation Grant and Academic Health Center Faculty Research Development Grant)
- Prospect Creek Foundation
- American Chemical Society Division of Medicinal Chemistry (ACS MEDI)
- NIH [F31-CA183246, P30-CA77598]
Ask authors/readers for more resources
High-throughput screening (HTS) was employed to discover APOBEC3G inhibitors, and multiple 2-furylquinolines (e.g., 1) were found. Dose response assays with 1 from the HTS sample, as well as commercial material, yielded similar confirmatory results. Interestingly, freshly synthesized and DMSO-solubilized 1 was inactive. Repeated screening of the DMSO aliquot of synthesized 1 revealed increasing APOBEC3G inhibitory activity with age, suggesting that 1 decomposes into an active inhibitor. Laboratory aging of 1 followed by analysis revealed that 1 undergoes oxidative decomposition in air, resulting from a [4 + 2] cycloaddition between the furan of 1 and O-1(2). The resulting endoperoxide then undergoes additional transformations, highlighted by Baeyer-Villager rearrangements, to deliver lactam, carboxylic acid, and aldehyde products. The endoperoxide also undergoes hydrolytic opening followed by further transformations to a bis-enone. Eight structurally related analogues from HTS libraries were similarly reactive. This study constitutes a cautionary tale to validate 2-furylquinolines for structure and stability prior to chemical optimization campaigns.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available